Experts: India’s New IP Policy Shows Good Intent But Needs Timelines
This article was originally published in PharmAsia News
A group representing multinational pharmaceutical companies in India has praised the government's new national intellectual property rights policy for embracing a "culture of innovation" but says the policy needs more teeth to truly protect patents and trademarks.
You may also be interested in...
India’s more muscular intellectual property protection policy is a good first step but the government will have to “walk the talk” to attract significant new investment from global pharmaceutical companies, say US experts. Implementation of the policy will be the key measure of its success, they say.
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.